Latest News

  • Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference Read More
  • Alkermes Completes Acquisition of Rodin Therapeutics Read More
  • Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Read More

Investors

Working at Alkermes